What is the clinical evidence from this study?

Study design: Review. Population: Diabetic silent myocardial ischemia.

What question did this study set out to answer?

This review aims to explore the mechanisms underlying diabetic silent myocardial ischemia and suggest potential biomarkers and therapies.

June 22, 2026Microvascular Research

Microvascular dysfunction and neurovascular signalling impairment in diabetic silent myocardial ischemia

Q: What does this research mean for the field?

Diabetic silent myocardial ischemia is driven by converging pathways of coronary microvascular dysfunction and neurocardiac signaling disruption, with mitochondrial dysfunction acting as a shared mechanistic link. Novelty: ClaimNovelty.SYNTHESIS. Consensus alignment: ConsensusAlignment.NEUTRAL.

View Full Paper

Ask AI

Bookmark

Key result

Microvascular and neurocardiac disruptions drive diabetic silent myocardial ischemia via mitochondrial dysfunction.

Why the study?

Diabetic silent myocardial ischemia represents a clinically underappreciated yet life-threatening complication where impaired myocardial perfusion occurs without recognisable symptoms.

Design

Review

Authors

HRHarishkaruppiah RKarunya University

Discussion

Member takes

Implication

May inform targeted mechanistic studies in diabetic silent ischemia; leaves open clinical translation pending prospective validation.

Key Points

This review aims to explore the mechanisms underlying diabetic silent myocardial ischemia and suggest potential biomarkers and therapies.
Synthesis of current mechanistic knowledge regarding coronary microvascular dysfunction and neurocardiac signalling impairment.
Identification of candidate biomarkers for early diagnosis, including urinary 8-OHdG and NT-proBNP.
Proposal of actionable therapeutic targets, including mitochondria-directed antioxidants and receptor modulators.
Highlighting the roles of oxidative stress and mitochondrial dysfunction in microvascular and neurovascular impairment.
Identification of biomarkers that could aid in early diagnosis and management of diabetic silent myocardial ischemia.
Proposal of various therapeutic strategies targeting mitochondrial function and neurovascular signalling.

Structured PICO

Population

Diabetic patients with silent myocardial ischemia (DSMI)

This review provides a unified mechanistic framework for diabetic silent myocardial ischemia, highlighting the interplay between microvascular dysfunction and neuropathy, and identifies potential biomarkers and therapeutic targets.

Cite This Study

Harishkaruppiah R (2026) conducted a review in Diabetic silent myocardial ischemia. Diabetic silent myocardial ischemia is driven by coronary microvascular dysfunction and neurocardiac signaling disruption, with mitochondrial dysfunction serving as a shared mechanistic node.

synapsesocial.com/papers/6a394a596b40f64ab5dab393 https://doi.org/10.1016/j.mvr.2026.104983

View Full Paper

Ask AI

Bookmark

Microvascular dysfunction and neurovascular signalling impairment in diabetic silent myocardial ischemia

Discussion

Member takes

Implication

Key Points

Structured PICO

Cite This Study

Microvascular dysfunction and neurovascular signalling impairment in diabetic silent myocardial ischemia

Discussion

Member takes

Implication

Key Points

Structured PICO

Cite This Study

Also Consider

Also Consider